Nilotinib: all 136 studies that test it
Page 2 of 2. Open to participants first (8), then studies with results posted, then the rest; newest registration first within each.
- Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to ImatinibStatus unknownNCT01400074Phase 3
- A Trial Looking at Nilotinib to Treat Acral and Mucosal Melanoma Skin Cancer That Has SpreadCompletedNCT01395121Phase 2
- Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 TrialCompletedNCT01368523Phase 4
- Gleevec as Maintenance Therapy After Cytogenetic Response With Nilotinib in Newly Diagnosed Chronic Myelogenous LeukemiaCompletedNCT01316250Not applicable
- Study to Evaluate Nilotinib in Adult Patients With Imatinib-resistant or Imatinib-intolerant Chronic Myelogenous Leukemia (CML), or Relapse/Refractory Ph+ Acute Lymphoblastic Leukemia (ALL) (Extension Study)CompletedNCT01279473Phase 1/2
- Tasigna Neoadjuvant Gastrointestinal Stromal Tumor (GIST)WithdrawnNCT01270893Phase 2
- Study of Nilotinib Efficacy in Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour (PVNS/TGCT)CompletedNCT01261429Phase 2
- Nilotinib for Cytomegalovirus Prophylaxis and Treatment After Allogeneic Hematopoietic Stem Cell TransplantationCompletedNCT01252017Phase 2
- To Evaluate the Effects of Multiple Doses of Nilotinib on the Pharmacokinetics and Metabolism of Midazolam in CML Patients With Additional Extension Phase to Evaluate the Safety of NilotinibCompletedNCT01223898Phase 1
- Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and High-dose Cytarabine Induction Chemotherapy Followed by Consolidation for Patients With C-kit Positive Acute Myeloid LeukemiaTerminatedNCT01222143Phase 1/2
- Determining the Maximum Tolerated Dose of Low Dose Interferon-alpha in Conjunction With Nilotinib in Pretreated Philadelphia Chromosome Positive (Ph+) Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP)CompletedNCT01220648Phase 1
- Tasigna in Glivec-resistant or Intolerant Patients in CMLCompletedNCT01206088Phase 4
- A Study of Nilotinib in Growing Vestibular SchwannomasTerminatedNCT01201538Phase 2
- Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas.Status unknownNCT01168050Phase 2
- Phase 1 Nilotinib in Steroid Dependent/Refractory Chronic Graft Versus Host DiseaseCompletedNCT01155817Phase 1
- A Study of Nilotinib in Adult Patients With Imatinib Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic PhaseCompletedNCT01126892Phase 3
- Evaluation of Nilotinib In Patients With Advanced Gastrointestinal Stromal Tumor (GIST)CompletedNCT01110668Phase 2
- Study of Nilotinib in Metastatic Melanoma With KIT AberrationsCompletedNCT01099514Phase 2
- Ph+/Bcr-Abl+ ALL Imatinib and Nilotinib Rotational StudyCompletedNCT01025505Phase 2
- Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic LeukemiaTerminatedNCT00905398Phase 1/2
- Nilotinib in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00809211Phase 2
- Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic PhaseCompletedNCT00786812Phase 4
- Nilotinib and Imatinib Mesylate in Treating Patients With Early Chronic Phase Chronic Myelogenous LeukemiaCompletedNCT00769327Phase 2
- Combination of Nilotinib (AMN107) and RAD001 in Patients With Acute Myeloid LeukemiaCompletedNCT00762632Phase 1/2
- Nilotinib Pre and Post Allogeneic Stem Cell TransplantationCompletedNCT00750659Phase 2
- Effect of Calcium on Tasigna Pharmacokinetics (PK) in Healthy VolunteersCompletedNCT00732888Phase 1
- Efficacy and Safety of AMN107 in Patients With GastroIntestinal Stromal Tumors (GIST) Who Have Failed Both Imatinib and SunitinibCompletedNCT00718562Phase 2
- Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) InhibitorCompletedNCT00633295Phase 2
- Nilotinib as First-line Treatment of Ph+ CML in Early Chronic PhaseCompletedNCT00481052Phase 2
- Patients Completing Core Protocol (CAMN107A2103), Exhibiting Stable Disease (SD), Partial Response (PR) or Complete Response (CR) to Nilotinib in Combination With ImatinibCompletedNCT00441155Phase 1
- Bioavailability Study Comparing Two New Nilotinib Tablet Formulations to an Established Nilotinib Capsule Formulation in Healthy VolunteersCompletedNCT00418769Phase 1
- Effects of Rifampin on the Pharmacokinetics of Nilotinib in Healthy SubjectsCompletedNCT00418756Phase 1
- Pharmacokinetics of Nilotinib in Subjects With Impaired Hepatic Function and Healthy Subjects With Normal Hepatic FunctionCompletedNCT00418626Phase 1
- A Phase l/ll Study of AMN107 in Adult Patients With Glivec-intolerant CML or Relapsed-refractory Ph+ALLCompletedNCT00384228Phase 1/2
- Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate TherapyCompletedNCT00264160Phase 2/3
- Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)CompletedNCT00135005Phase 1